The Future of Cardiovascular Therapeutics.
From Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (C.A.M., J.L.); Harvard Medical School, Boston, MA (C.A.M., J.L.); and Cardiology Division, Department of Medicine, Vanderbilt University Medical School, Nashville, TN (D.M.R.). camacrae@bics.bwh.harvard.edu.
Calum A
CA
MacRae
From Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (C.A.M., J.L.); Harvard Medical School, Boston, MA (C.A.M., J.L.); and Cardiology Division, Department of Medicine, Vanderbilt University Medical School, Nashville, TN (D.M.R.).
Dan M
DM
Roden
From Cardiovascular Medicine Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (C.A.M., J.L.); Harvard Medical School, Boston, MA (C.A.M., J.L.); and Cardiology Division, Department of Medicine, Vanderbilt University Medical School, Nashville, TN (D.M.R.).
Joseph
J
Loscalzo
D000818:Animals; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D055808:Drug Discovery / Q000639:trends*; D005544:Forecasting; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends*; D057285:Precision Medicine / Q000639:trends; D016896:Treatment Outcome
D002317:Cardiovascular Agents
cardiovascular diseases; genetics; genomics; informatics; therapeutics